|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/675 | |
| A61K 31/506 | |||
| A61K 31/404 | |||
| A61K 31/436 | |||
| A61K 31/665 | |||
| A61K 31/44 | |||
| A61K 39/395 | |||
| A61P 35/00 | |||
| A61K 45/06 | |||
| A61K 31/4045 | |||
| A61K 31/4412 | |||
| A61P 35/02 | |||
| A61P 43/00 |
| (11) | Number of the document | 3311835 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17187097.5 |
| Date of filing the European patent application | 2011-07-11 | |
| (97) | Date of publication of the European application | 2018-04-25 |
| (45) | Date of publication and mention of the grant of the patent | 2021-03-24 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 363610 P | 2010-07-12 | US | |
| 201161470412 P | 2011-03-31 | US | |
| 201161470812 P | 2011-04-01 | US |
| (72) |
KROLL, Stewart, US
CURD, John, US
HART, Charles, US
SUN, Jessica, US
|
| (73) |
ImmunoGenesis, Inc. ,
909 Fannin, Suite 2000, Houston, TX 77010,
US
|
| (54) | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER |
| ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER |